Does glycoprotein IIB/IIIA resistance exist?

Netherlands Heart Journal

Volumn 15, Issue 11, 2007, Pages 367-368

  Smit, J J J ^a   Van 'T Hof, A W J ^a  

^a ISALA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; TIROFIBAN;

ACUTE CORONARY SYNDROME; BLOOD CLOT LYSIS; BLOOD CLOTTING PARAMETERS; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; EDITORIAL; GERMANY; HEART INFARCTION; HUMAN; LOW DRUG DOSE; NETHERLANDS; PERCUTANEOUS CORONARY INTERVENTION; ST SEGMENT ELEVATION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOSIS; TREATMENT OUTCOME;

EID: 36749080996     PISSN: 15685888     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03086016     Document Type: Editorial

References (16)

1. Matetzky S, Shenkman B, Guetta V, Shechter M, Bienart R, Goldenberg I, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004;109:3171-5.
2. Gurbel PA, Bliden KP, Samara W, Yoho JA, Hayes K, Fissha MZ, et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol 2005;46:1827-32.
3. Gibson CM, Jennings LK, Murphy SA, Lorenz DP, Giugliano RP, Harrington RA, et al. for the INTEGRITI Study Group. Association between platelet receptor occupancy after eptifibatide (integrilin) therapy and patency, myocardial perfusion, and ST-segment resolution among patients with ST-segment-elevation myocardial infarction: an INTEGRITI (Integrilin and Tenecteplase in Acute Myocardial Infarction) substudy. Circulation 2004;110:679-84.
4. Frossard M, Fuchs I, Leitner JM, Hsieh K, Vlcek M, Losert H, et al. Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation 2004;110:1392-7.
5. de Prado AP, Fernandez-Vazquez F, Cuellas JC, Alonso-Orcajo N, Carbonell R, Pascual C, et al. Association between level of platelet inhibition after early use of abciximab and myocardial reperfusion in ST-elevation acute myocardial Infarction treated by primary percutaneous coronary intervention. Am J Cardiol 2006;97:798-803.
6. van Werkum JW, Gerritsen WBM, Kelder JC, Hackeng CM, Deneer VHM, Suttorp MJ, et al. Inhibition of platelet function by abciximab or high-dose tirofiban in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial. Neth Heart J 2007;15:375-81.
7. Schneider DJ, Herrmann HC, Lakkis N, Aguirre F, Wan Y, Aggarwal A, et al. Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban. Am J Cardiol 2002;90:1421-1424.
8. Kabbani SS, Aggarwal A, Terrien EF, DiBattiste PM, Sobel BE, Schneider DJ. Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions. Am J Cardiol 2002;89:647-50.
9. Harrington RA, Kleiman NS, Kottke-Marchant K, et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol 1995;76:1222-7.
10. Tcheng JE, Ellis SG, George BS, et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation 1994;90:1757-64.
11. Ernst NMSKJ, Suryapranata H, Miedema K, et al. Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST segment elevation myocardial infarction. J Am Coll Cardiol 2004;44:1187-93.
12. Smit JJJ, Hoorntje JCA, Miedema K, van Oeveren W. Impaired platelet inhibitory effect of a single dose acetylsalicylic acid in patients with unstable coronary artery syndrome in comparison with healthy volunteers. Neth Heart J 2004;12:265-70.
13. Gurbel PA, Bliden KP, DiChiara J, Newcomer J, Weng W, Neerchal NK, et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation 2007;115:3156-64.
14. Rocca B, Patrono C. Determinants of the interindividual variability in response to antiplatelet drugs. J Thromb Haemost 2005;3:1597-602.
15. Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005;45(2):246-51.
16. Van 't Hof AWJ, Hamm C, Rasoul S, et al. Ongoing tirofiban in myocardial infarction evaluation (On-TIME) 2 trial: rationale and study design. Eurointervention 2007, published online, ahead of print.